期刊文献+

塞来昔布醇质体凝胶的制备及其透皮吸收研究 被引量:8

Preparation and Transdermal Penetration of the Gel Based on Celecoxib Ethosomes
原文传递
导出
摘要 采用乙醇注入法制备塞来昔布醇质体,以超速离心法测定包封率,用其为评价指标,通过正交设计优化处方。所得优化处方在透射电镜下呈球形,包封率为(72.56±0.29)%,动态光散射法测得其粒径(189.4±0.8)nm,多分散系数为0.322±0.012,ζ电位为(-21.58±0.26)m V。以卡波姆934为凝胶基质,分别制备了基于塞来昔布醇质体的凝胶和普通凝胶。以小鼠为模型的离体透皮试验结果表明,塞来昔布醇质体凝胶与普通凝胶的稳态渗透速率为(17.89±0.18)和(7.62±0.12)μg·cm^(-2)·h^(-1),12 h时皮肤滞留量为(13.62±0.17)和(5.69±0.25)μg/cm^2。可见,塞来昔布醇质体凝胶能显著增加药物的渗透速率与皮肤滞留量,是一种较有前景的经皮给药系统。 The celecoxib ethosomes were prepared by ethanol injection method and the entrapment efficiency was detemined by ultracentrifugation. The formulation of the ethosomes was optimized by orthogonal design with entrapment efficiency as the index. The morphology of the optimal ethosomes was observed by transmission electron microscopy (TEM), and the partical size and ζ potential were conducted with the help of dynamic light scattering. The results showed that the optimal product had a spherical shape with the mean entrapment efficiency of (72.56±0.29)%.The average partical size, polydispersity index and ζ potential were (189.4±0.8)nm, 0.322±0.012 and (-21.58±0.26)mV,respectively. Then, the gels based on the optimal ethosomes and the bulk drug were prepared with Carbopor 934 as a gel matrix. The in vitro transdermal test were carried out with excised mouse skin as the barriers to compare the permeation amount and skin retention of the above two gels. The results showed that the steady penetration rates of celecoxib ethosomal gel and celecoxib gel were (17.89±0.18) and (7.62±0.12)μg·cm-2·h-1, while the retention amounts at 12 h were (13.62±0.17) and (5.69±0.25)μg/cm2. It indicated that the celecoxib ethosomal gel might to be a promising carrier of transdermal delivery for celecoxib because of the significant increasing in both the permeation rate and skin retention.
作者 郝贵周 管圆圆 张贵民 HAO Guizhou GUAN Yuanyuan ZHANG Guimin(National Chiral Pharmaceuticals Engineering and Technology Research Center, Lunan Pharmaceutical Group Co., Ltd., Linyi 27340)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第6期869-873,共5页 Chinese Journal of Pharmaceuticals
关键词 塞来昔布 醇质体 凝胶 渗透速率 皮肤滞留量 经皮给药 celecoxib ethosome gel permeation rate skin retention transdermal delivery
  • 相关文献

参考文献4

二级参考文献42

  • 1张青,朱家壁,邱丽梅.盐酸左氧氟沙星脂质体的包封率和体外释放研究[J].中国药科大学学报,2004,35(6):508-512. 被引量:9
  • 2黄洁 仵文英.脂质体制剂抗肿瘤应用及研究进展.西部药学,2007,4(3):158-160.
  • 3OH YK, Nix D E, Straudinger R M. Formulation and efficiency of liposome - encapsulated antibiotics for therapy of intraceUular Mycobacteroum avium infection [J ]. Antimierob Agents Chemother, 1995, 39:2 104 - 2 111.
  • 4Lasic D D, Frederik P M, Strart M C A, et al. Gelation of liposome interior [J]. FEBS, 1992, 312(2, 3): 255 - 258.
  • 5HWANG C. Overcoming docetaxel resistance in prostate cancer: a perspective review[J]. Ther Adv Med Oncol , 2012,4(6):329-340.
  • 6MITA AC, DENIS LJ, ROWINSKY EK, et al. Phase Ⅰ and phar- macokinetic study of XRP6258 (RPR 116258A) , a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors [ J 1. Clin Cancer Res ,2009,15 (2) :723 - 730.
  • 7PIVOT X, KORALEWSKI P, HIDALGO JL,et al. A muhicenter phase Ⅱ study of XRP6258 administered as a 1-h i. v. infusion ev- ery 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008,19(9) :1547 - 1552.
  • 8DE BONO JS, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxe! treatment: a randomised open-label trial [ J ]. Lancet, 2010,376 ( 9747 ) : 1147 - 1154.
  • 9BECZE E. Manage side effects of cabazitaxel in patients with castrate- resistant prostate cancer[ J]. ONS Connect, 2012,27(9) :16 -17.
  • 10Cabazitaxet at 20 mg'm 2 compared to 25 mg'm 2 with predni- sone for the treatment of metastatic castration resistant prostate cancer(PROSELICA) [ EB/OL ]. http ://www. clinicahrials, gov/ et2/results? term = eabazitaxel&Search.

共引文献16

同被引文献126

引证文献8

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部